2k17 BATCH GM 1ST INTERNAL ASSESSMENT : OCT-2021
1. Define bone density, how is it measured? What are the causes, clinical features, diagnosis and management of osteoporosis? (1+2+2+2+3)
- Sex. Your chances of developing osteoporosis are greater if you are a woman. Women have lower peak bone mass and smaller bones than men. However, men are still at risk, especially after the age of 70.
- Age. As you age, bone loss happens more quickly, and new bone growth is slower. Over time, your bones can weaken and your risk for osteoporosis increases.
- Body size. Slender, thin-boned women and men are at greater risk to develop osteoporosis because they have less bone to lose compared to larger boned women and men.
- Race. White and Asian women are at highest risk. African American and Mexican American women have a lower risk. White men are at higher risk than African American and Mexican American men.
- Family history. Researchers are finding that your risk for osteoporosis and fractures may increase if one of your parents has a history of osteoporosis or hip fracture.
- Changes to hormones. Low levels of certain hormones can increase your chances of developing osteoporosis. For example:
- Low estrogen levels in women after menopause.
- Low levels of estrogen from the abnormal absence of menstrual periods in premenopausal women due to hormone disorders or extreme levels of physical activity.
- Low levels of testosterone in men. Men with conditions that cause low testosterone are at risk for osteoporosis. However, the gradual decrease of testosterone with aging is probably not a major reason for loss of bone.
- Diet. Beginning in childhood and into old age, a diet low in calcium and vitamin D can increase your risk for osteoporosis and fractures. Excessive dieting or poor protein intake may increase your risk for bone loss and osteoporosis.
- Other medical conditions. Some medical conditions that you may be able to treat or manage can increase the risk of osteoporosis, such as other endocrine and hormonal diseases, gastrointestinal diseases, rheumatoid arthritis, certain types of cancer, HIV/AIDS, and anorexia nervosa.
- Medications. Long-term use of certain medications may make you more likely to develop bone loss and osteoporosis, such as:
- Glucocorticoids and adrenocorticotropic hormone, which treat various conditions, such as asthma and rheumatoid arthritis.
- Antiepileptic medicines, which treat seizures and other neurological disorders.
- Cancer medications, which use hormones to treat breast and prostate cancer.
- Proton pump inhibitors, which lower stomach acid.
- Selective serotonin reuptake inhibitors, which treat depression and anxiety.
- Thiazolidinediones, which treat type II diabetes.
- Lifestyle. A healthy lifestyle can be important for keeping bones strong. Factors that contribute to bone loss include:
- Low levels of physical activity and prolonged periods of inactivity
- Chronic heavy drinking of alcohol is a significant risk factor for osteoporosis.
- Studies indicate that smoking is a risk factor for osteoporosis and fracture.
Bones affected by osteoporosis may become so fragile that fractures occur spontaneously or as the result of:
- Minor falls, such as a fall from standing height that would not normally cause a break in a healthy bone.
- Normal stresses such as bending, lifting, or even coughing.
The goals for treating osteoporosis are to slow or stop bone loss and to prevent fractures. Your health care provider may recommend:
- Proper nutrition.
- Lifestyle changes.
- Exercise.
- Fall prevention to help prevent fractures.
- Medications.
2. What is myxedema coma? Describe its clinical features, diagnosis and treatment of myxedema coma? (2+2+2+4)
Myxedema coma is a rare fatal condition as a result of long-standing hypothyroidism with loss of the adaptive mechanism to maintain homeostasis. Hypothyroidism due to any cause,, including autoimmune disease, iodine deficiency, congenital abnormalities, or medications like lithium and amiodarone, can precipitate myxedema coma if left untreated.
Its a misnomer as patient may present with a spectrum ranging from depression psychosis to coma.
Clinical features:
CVS : Common cardiovascular symptoms include hypotension, shock, arrhythmia, and heart block. Myxedema causes decreased myocardial contractility (bradycardia) and reduced cardiac output, which leads to hypotension.
CNS: depression, disorientation, decrease deep tendon reflexes, psychosis, slow mentation, paranoia, and poor recall.One case describes a rare presentation of a patient with status epilepticus.
RESPIRATORY: Hypoventilation in myxedema coma is due to impaired hypoxic and hypercapnic ventilatory response and the associated diaphragmatic muscle weakness
GIT: Myxedema coma commonly causes abdominal pain, nausea, vomiting, ileus, anorexia, and constipation. Ileus is of particular importance as it can lead to megacolon. Ascites has also been seen in cases of myxedema
RENAL : Typical findings in myxedema coma are hyponatremia and decreased glomerular filtration rate. Hyponatremia occurs mainly due to decreased water transport to the distal nephron. Other causes can be an increase in antidiuretic hormone (ADH). Hyponatremia is also a key factor in the patient’s altered mental status and development of coma
Diagnosis:
Clinically : Altered mental status with hypothermia
Lab investigation:
• Septic workup to rule out infection, including cultures and chest X-ray, etc.
• EKG (can show bradycardia with non-specific changes, decrease voltage, variable block, or prolong QT interval)
• Arterial blood gases can show hypoxia, hypercapnia, and respiratory acidosis.
• If cardiomegaly is present on imaging studies, further investigations to rule out pericardial effusion are necessary (echocardiogram is a necessary follow-up)
• Thyroid profile : severely low or undetected low serum total T4, free T4, free T3, and elevated TSH.
Treatment:
The identification of the precipitating factor is essential. Respiratory and airway management is a critical component in the management of the patient. Frequent monitoring of the arterial blood gas should be performed to monitor the hypercapnia and hypoxemia. Most will require mechanical ventilation as the altered mental status does leave patients more prone to aspiration, and airway obstruction could occur due to the myxedema of the larynx.
According to the most recent American Thyroid Association (ATA) guidelines, the recommended initial dose is 200 to 400 mcg IV once (lower dose for elderly, or underlying cardiac disease or arrhythmia with some reports up to 500 mcg). Subsequently, dosing is 1.6 mcg/kg/day, reduced to 75% when given IV as a preferred route, for patients may not be able to tolerate PO, and the absorption could be impaired secondary to intestinal impaired motility and edema.
Hyponatremia : 3% NaCl infusion
Cardiac temponade : pericardiocentasis
Adrenal insuffienciency : Hydrocortisone 100 mg iv TID
https://www.ncbi.nlm.nih.gov/books/NBK545193/
In peripheral blood smear (PBS), megaloblasts, while not pathognomic, are highly suggestive of megaloblastic anemia. The changes are not limited to red blood cells, and hypersegmented neutrophils, with six or more lobes, may be present. Other findings include Howell-Jolly bodies, anisocytosis, and poikilocytosis.
If there are megaloblasts on PBS with a high reticulocyte count, the first-line investigation includes an assay of vitamin B12 and folate red blood cell levels. Levels of less than 200 pg/ml of vitamin B12 indicate a deficiency.
Treatment:
patients receive 1000 ug of vitamin B12 daily in their first week of treatment. In the following month, they receive weekly and then monthly injections.
Usually, reticulocytosis occurs within 3 to 5 days. By the tenth day, hemoglobin starts to increase, and a total resolution of anemia normally occurs after 2 months of treatment.
https://www.ncbi.nlm.nih.gov/books/NBK537254/
- Alcohol use
- Gallstones
- Hypertriglyceridemia
- Idiopathic
- Drug-induced pancreatitis
- Post-procedural (endoscopic retrograde cholangiopancreatography or abdominal surgery)
- Ampullary stenosis is formerly known as sphincter of Oddi dysfunction type I
- Autoimmune pancreatitis, type I (systemic IgG4 disease-related), and type II
- Viral infection (Coxsackie, Cytomegalovirus, Echovirus, Epstein-Barr virus, Hepatitis A/B/C, HIV, Mumps, Rubella, Varicella)
- Bacterial infection (Campylobacter jejuni, Legionella, Leptospirosis, Mycobacterium avium, Mycobacterium tuberculosis, Mycoplasma)
- Trauma
- Smoking
- Congenital anomalies (annular pancreas)
- Genetic disorders (hereditary pancreatitis, cystic fibrosis, alpha 1-antitrypsin deficiency)
- Hypercalcemia
- Parasitic infections (Ascaris lumbricoides, Cryptosporidium, Clonorchis sinensis, Microsporidia)
- Renal disease (Hemodialysis)
The first abnormality that develops is portal hypertension in the case of cirrhosis. Portal pressure increases above a critical threshold and circulating nitric oxide levels increase, leading to vasodilatation. As the state of vasodilatation becomes worse, the plasma levels of vasoconstrictor sodium-retentive hormones elevate, renal function declines, and ascitic fluid forms, resulting in hepatic decompensation.
Through the production of proteinous fluid by tumor cells lining the peritoneum, peritoneal carcinomatosis also can cause ascites. In high-output or low-output heart failure or nephrotic syndrome, effective arterial blood volume is decreased, and the vasopressin, renin-aldosterone, and sympathetic nervous systems are activated, leading to renal vasoconstriction and sodium and water retention.
The initial tests that should be performed on the ascitic fluid include a blood cell count, with both a total nucleated cell count and polymorphonuclear neutrophils (PMN) count, and a bacterial culture by bedside inoculation of blood culture bottles.
Ascitic fluid protein and albumin are measured simultaneously with the serum albumin level to calculate the serum-ascites albumin gradient (SAAG).
The presence of a gradient greater or equal to 1.1 g/dL (greater or equal to 11 g/L) predicts that the patient has portal hypertension with 97% accuracy. This is seen in cirrhosis, alcoholic hepatitis, heart failure, massive hepatic metastases, heart failure/pericarditis, Budd-Chiari syndrome, portal vein thrombosis, and idiopathic portal fibrosis. A gradient less than 1.1 g/dL (less than 11 g/L) indicates that the patient does not have portal hypertension and occurs in peritoneal carcinomatosis, peritoneal tuberculosis, pancreatitis, serositis, and nephrotic syndrome.
LDH and glucose level should be determined in suspected cases of secondary peritonitis.
Other tests to consider include amylase (greater than 1000 U/L suggests pancreatic ascites).
CT scan can also be used to detect ascites and may also help determine for presence of any masses.
9. Mention the differences in findings between UMN and LMN lesion?
Renal Indications
- Oliguria/Anuria with volume overload
- Uremia with symptoms
- Refractory Hyperkalemia ( K+ over 6.0)
- Refractory Metabolic acidosis due to renal failure (pH < 7.2)
- Acute pulmonary edema
Non-renal Indications
- Removal of dialysable toxins, i.e. ones which aren’t very lipophilic or protein-bound
- Lithium
- Methanol
- Ethylene glycol
- Salicylates
- Theophylline
- Valproate
- Pretty much any drug with a volume of distribution less than 0.5L/kg
- Removal of contrast agent
- Clearance of cytokines to decrease severity of sepsis
Still controversial. May be of use in patients with renal failure and sepsis.
No evidence that it helps in patients with sepsis who don’t have renal failure.
- Control of body temperature
An extracorporeal circuit can help control hypo or hyperthermia which is resistant to other methods of control.
- Control of otherwise uncontrollable electrolytes
Hypercalcemia refractory to pamidronate, for one example.
Intrahepatic causes of portal hypertension
Intrahepatic causes of portal hypertension include cirrhosis and hepatic fibrosis or scarring. A wide variety of illnesses are implicated as the cause of portal hypertension. Examples include the following:
- Alcohol abuse,
- Hepatitis B and C infections,
- Fatty liver (NASH, non-alcoholic steatohepatitis),
- Wilson's disease, an abnormality of copper metabolism,
- Hemochromatosis (iron overload), excess iron buildup
- Cystic fibrosis
- Primary sclerosing cholangitis, a hardening of the bile ducts
- Biliary atresia, poorly formed bile ducts
- Parasite infections such as schistosomiasis
Pre-hepatic causes of portal hypertension
Portal vein thrombosis or blood clots within the portal veinCongenital portal vein atresia or failure of the portal vein to develop
Post-hepatic causes of portal hypertension
Post-hepatic causes are due to obstruction of blood flow from the liver to the heart and can include:
- Hepatic vein thrombosis
- Inferior vena cava thrombosis
- Restrictive pericarditis, where the lining of the heart stiffens and does not allow the heart to relax and expand when blood returns to it. Causes may include tuberculosis, fungal infections, tumors, connective tissue disorders (for example, scleroderma), and complications from radiation therapy.
- Flattened face
- Small head
- Short neck
- Protruding tongue
- Upward slanting eye lids (palpebral fissures)
- Unusually shaped or small ears
- Poor muscle tone
- Broad, short hands with a single crease in the palm - simian crease
- Relatively short fingers and small hands and feet
- Excessive flexibility
- Tiny white spots on the colored part (iris) of the eye called Brushfield's spots
- Short height
- Intellectual disability : mild to moderate cognitive impairment. Language is delayed, and both short and long-term memory is affected.
During the acute phase:
- Congestive heart failure
- Azotemia
- Chronic kidney disease
- Nephrotic syndrome.
16. Causes of cervical myelopathy?
- Congenital spinal stenosis
- Bulging or herniated discs and bone spurs in the neck.
- Ossification (hardening) of the ligaments surrounding the spinal cord, such as posterior longitudinal ligament and ligamentum flavum.
- Rheumatoid arthritis of the neck
- Whiplash injury or other cervical spine trauma
- Spinal infections
- Spinal tumors and cancers
Comments
Post a Comment